Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil
| Autor: | Angelo Alves de Mattos, Henrique Mirenda, Camila V Pereira, Paulo Roberto Lerias de Almeida, Thiago Kreutz Grossmann, Cristiane Valle Tovo, Bruna B Dal-Pupo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Microbiology (medical)
Male medicine.medical_specialty Hepatitis B virus lcsh:Arctic medicine. Tropical medicine Guanine Tenofovir lcsh:RC955-962 lcsh:QR1-502 viral hepatitis medicine.disease_cause Antiviral Agents lcsh:Microbiology 03 medical and health sciences 0302 clinical medicine Hepatitis B Chronic Chronic hepatitis medicine Humans 030212 general & internal medicine Hepatitis B e Antigens Adverse effect therapy Hepatitis B Surface Antigens business.industry nucleos(t)ide analogues Public health Entecavir Articles Middle Aged Viral Load medicine.disease Virology Cross-Sectional Studies Treatment Outcome DNA Viral 030211 gastroenterology & hepatology Female Public Health business Viral hepatitis Viral load hepatitis B virus medicine.drug |
| Zdroj: | Memórias do Instituto Oswaldo Cruz, Volume: 111, Issue: 4, Pages: 252-257, Published: APR 2016 Memórias do Instituto Oswaldo Cruz Memórias do Instituto Oswaldo Cruz., Vol 111, Iss 4, Pp 252-257 (2016) |
| Popis: | There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the present study was to assess the effectiveness of the nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the treatment of chronic HBV. A cross-sectional study was carried out from March-December 2013, including all patients with chronic HBV, over 18 years of age, undergoing therapy through the public health system in southern Brazil. Only the data relating to the first treatments performed with TDF or ETV were considered. Retreatment, co-infection, transplanted or immunosuppressed patients were excluded. Six hundred and forty patients were evaluated, of which 336 (52.5%) received TDF and 165 (25.8%) ETV. The other 139 (21.7%) used various combinations of nucleos(t)ide analogues and were excluded. The negativation of viral load was observed in 87.3% and 78.8% and the negativation of hepatitis B e antigen was achieved in 79% and 72% of those treated with ETV or TDF, respectively. Negativation of hepatitis B surface antigen was not observed. There was no occurrence of adverse effects. This is a real-life study demonstrating that long-term treatment with ETV and TDF is both safe and effective. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|